Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Leerink Swann dropped their Q3 2017 EPS estimates for shares of Aclaris Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the biotechnology company will post earnings of ($0.84) per share for the quarter, down from their previous estimate of ($0.81). Leerink Swann also issued estimates for Aclaris Therapeutics’ Q4 2017 earnings at ($1.00) EPS, FY2017 earnings at ($2.89) EPS, FY2018 earnings at ($3.37) EPS, FY2019 earnings at ($1.68) EPS and FY2020 earnings at ($1.33) EPS.
ACRS has been the subject of a number of other research reports. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, June 6th. Jefferies Group LLC set a $36.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 20th. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research note on Friday, June 16th. They issued an “overweight” rating and a $50.00 price target for the company. Finally, BidaskClub cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $39.00.
TRADEMARK VIOLATION WARNING: “Q3 2017 Earnings Estimate for Aclaris Therapeutics, Inc. Issued By Leerink Swann (NASDAQ:ACRS)” was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/2801318/q3-2017-earnings-estimate-for-aclaris-therapeutics-inc-issued-by-leerink-swann-nasdaqacrs.html.
Aclaris Therapeutics (NASDAQ ACRS) traded up 4.91% on Friday, reaching $24.15. 304,660 shares of the company’s stock were exchanged. The firm’s market cap is $645.67 million. Aclaris Therapeutics has a 12 month low of $18.74 and a 12 month high of $33.25. The firm’s 50-day moving average is $27.79 and its 200-day moving average is $27.96.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12.
A number of hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in shares of Aclaris Therapeutics by 253.1% in the first quarter. FMR LLC now owns 1,653,937 shares of the biotechnology company’s stock valued at $49,321,000 after buying an additional 1,185,598 shares during the period. Eagle Asset Management Inc. boosted its stake in shares of Aclaris Therapeutics by 287.3% in the second quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock valued at $36,828,000 after buying an additional 1,007,343 shares during the period. MARSHALL WACE ASIA Ltd acquired a new stake in shares of Aclaris Therapeutics during the first quarter valued at $21,116,000. Marshall Wace North America L.P. acquired a new stake in shares of Aclaris Therapeutics during the first quarter valued at $21,116,000. Finally, Franklin Resources Inc. boosted its stake in shares of Aclaris Therapeutics by 55.4% in the second quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after buying an additional 697,104 shares during the period. Institutional investors and hedge funds own 88.64% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.